FAQ
Semaglutide, a groundbreaking GLP-1 receptor agonist, was initially developed to help manage Type 2 diabetes. However, it soon gained attention for its remarkable side effect: significant weight loss. Clinical trials, including the STEP series, revealed that nearly 90% of participants lost 5% or more of their body weight, making it a standout option for weight management. With no other weight loss medication matching its results, semaglutide received FDA approval for weight loss in June 2022, revolutionizing treatment options for patients.
1
What are Semaglutide and Tirzepatide?
Semaglutide and Tirzepatide are medications that mimic the natural hormone GLP-1 to help reduce blood sugar levels and promote weight loss by controlling hunger and slowing the digestion process.
2
How do these medications work?
Semaglutide and Tirzepatide act like GLP-1 (a gut hormone) to:
-
Increase insulin production
-
Decrease glucagon synthesis
-
Delay gastric emptying
-
Suppress hunger. It signals to your brain that you're full so you can lose weight without feeling like you're depriving yourself.
3
What are potential side effects?
Commonly reported side effects include nausea, vomiting, constipation, fatigue, and headaches.
We complement treatment with lipotropic injections and essential vitamins to help minimize side effects. Our providers are also available to prescribe additional medications as needed to manage any side effects during transitional phases, ensuring a smooth and effective treatment experience.
4
Candidates for GLP-1 Medications
You are not a candidate for GLP-1 medications if you are pregnant, breastfeeding or under the age of 18. Patients with a history of gall bladder disease, pancreatitis, or medullary thyroid cancer should avoid GLP-1 medications.